Resurrect Bio Secures $8.1M in Series A to Enhance Crop Disease Resistance Capabilities
UK-based Resurrect Bio has raised $8.1 million in an initial closing of its Series A funding round, following a seed round of $2.1 million in 2023. Led by Corteva through its Catalyst platform, the investment will accelerate product development and team expansion. Resurrect Bio, spun out from The Sainsbury Laboratory in 2021, aims to restore plants' innate disease resistance by identifying protein interactions between crops and pathogens. The company is focusing on major crops like soy, corn, and wheat, with plans to deliver 18 disease resistance traits in the next three years.
Theia Market Signal Identification - AI Assisted
Resurrect Bio has raised $8.1 million in its Series A round, led by Corteva's Catalyst platform, to enhance crop disease resistance. The funding will support product development and team expansion. The company, established in 2021 from The Sainsbury Laboratory, works to restore plants' innate defenses against evolving pathogens by identifying binding interactions between plant immune receptors and pathogen proteins.
Its technology can apply to various crops and multiple threats, aiming for significant resistance improvements. Resurrect Bio is focusing on major crops like soy, corn, and wheat, with plans for 18 disease resistance traits in the next three years.
Comments